Research indicates that molecular markers such as IDH mutations (IDHmt) and 1p19q deletion (1p19q-codeletion) provide more precise prognostic information for patients with gliomas than previous methods, which relied largely on histopathological features. This evidence concerns the gene IDH2 and central nervous system cancer.